

3M India Limited WeWork Prestige Central 3rd Floor, 36 Infantry Road Bengaluru 560001, India Tel: +91 80 22231414 www.3M.com/in

June 1, 2023

The Corporate Relationship Department Bombay Stock Exchange Limited, 1st Floor, New Trading Ring, Rotunda Building P.J. Towers, Dalal Street, Fort Mumbai - 400 001

The Secretary
National Stock Exchange of India Limited
Exchange Plaza, Bandra – Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code - 3MINDIA

Scrip Code - 523395

Dear Sirs,

Sub: Meeting with Analyst/Institutional Investors- Outcome/Presentation.

Ref: Regulations 30 of SEBI (LODR) Regulations, 2015.

In pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 and in continuation of our earlier letter dated May 26, 2023 intimating scheduled Management Participation at the Annual Flagship Conference organized by B&K Securities convened on June 1, 2023, at Hotel Trident, BKC, Mumbai, please find attached Presentation made thereat.

This is for your information.

Thanking you,

Yours faithfully,

For 3M India Limited

Pratap Rudra Bhuvanagiri Company Secretary

Regd Office: Plot No 48-51 Electronics City, Bangalore 560100 CIN No: L31300KA1987PLC013543 Email: investorhelpdesk.in@mmm.com

PAN: AAACB5724H

GSTIN: 29AAACB5724H1ZQ





Safe Harbor Statement

This presentation by 3M India Limited (the "Company") is solely for general information purposes only and may not be taken away, distributed, reproduced, or passed on, directly or indirectly, to any other person or published in whole or in part, in any manner.

This presentation may contain certain statements with respect to the operations, performance and financial condition of the Company. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.

Nothing in this presentation should be construed as a forecast.

No representation or warranty, express or implied, is made as to and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions which may be contained in this presentation. Such information and opinions are in all events not current after the date of this presentation.

Agenda

- 3M Video
- 3M India Financial Results (Q4 & Full Year)
- Growth Focus
- Q & A





Incorporated in **1987**Publicly listed since **1991**



3 Manufacturing sites

1 R&D Center

2 Innovation Centers



INR 3959 crores (consol. FY 2022-23) +18.7% growth



1200+ Employees

FY 2022-23 Q4 & Full Year Consol. Results - Snapshot

Q4

Revenue & Growth

INR 1046 crores; +13.0%

PBT, PBT%, PBT growth

184 cr.; 17.5%; +21.7%

PAT, PAT%, PAT growth

136 cr.; 12.9%; +19.6%

Full Year

Revenue & Growth

INR 3959 crores; +18.7%

PBT, PBT%, PBT growth

607 cr.; 15.1%; +65.3%


PAT, PAT%, PAT growth

451 cr.; 11.2%; +65.8%


Serving our customers through four Business Groups

(FY 2022-23 consol sales in INR shown at bottom of slide with sales mix% & growth over prior year)









Transforming how work gets done

1301 cr.

33% mix + 9.0% growth Solving tough customer challenges to advance a connected world

1569 cr.

40% mix +33.6% growth **Enabling better, smarter, safer healthcare**

655 cr.


17% mix +18.6% growth Bringing 3M to the hearts and minds of consumers

410 cr.

10% mix +5.7% growth



Five Year Sales & PBT Trends (Consolidated)



Commentary on FY 2022-23 Financial Results

(consolidated)

Revenues:

- Strong performance in Transportation & Electronics and Health Care, both in Q4 and full year.
- De-stocking in Consumer in Q4.

Margin:

- Material Cost: 30bps improvement in Q4 and 50bps improvement full-year.
- Raw material & FX headwinds offset by price, mix and factory cost improvement actions.
- Spending discipline. Improved cost absorption.

Cash Flow:

432 crores (excl. dividend)

Growth Focus

- Automotive value chain (OEMs, tiers, after market)
- Penetration growth in prioritized industrial segments
- Infrastructure.

- Continued focus on practices in hospital settings.
- Consumer product portfolio.













INFUZE launch in partnership with INS India at the 8th INS India Annual conference

Update on Health Care Business

 Proposal for 3M India for continue to operate the Health Care business in India under a manufacturing and distributorship arrangement with the global company.

 Board of Directors of 3M India have granted approval for the management of 3M India to commence discussions and negotiations.

Q&A